Trial document
DRKS00009443
Trial Description
Title
Barostim Therapy™ in Heart Failure with Preserved Ejection Fraction (HFrEF): A Data Collection Registry with the CE-Marked Barostim neo™ System
Trial Acronym
HFrEF Registry
URL of the Trial
[---]*
Brief Summary in Lay Language
This registry is a collection of data in patients with an already implanted Barostim Therapy neo device for the treatment of hypertension and concomitant heart failure. The device itself is already approved for the treatment. At the following times data about the treatment are collected: before the device was implanted, and after 3, 6 and 12 months after the device was turned on.
Brief Summary in Scientific Language
The purpose of this registry is to measure the effect of Barostim Therapy with the Barostim Neo system in the commercial setting in subjects implanted under the CE Marked indication for heart failure with reduced ejection fraction (HFrEF).
Do you plan to share individual participant data with other researchers?
[---]*
Description IPD sharing plan:
[---]*
Organizational Data
- DRKS00009443
- 2015/10/05
- [---]*
- no
- Approved
- Nr. 6956, Ethikkommission der Medizinischen Hochschule Hannover
Secondary IDs
- 360049 ((CVRx Incorporated))
Health Condition or Problem studied
- I50.9 - Heart failure, unspecified
Interventions/Observational Groups
- Post-Market-Registerstudie: Patients with an implanted Barostim neo-system in accordance with CE-approved criteria for heart failure with reduced ejection fraction. Data regarding heart failure and device function will be collected at 3, 6 and 12 months after activation and will be compared to data prior to the implantation.
Characteristics
- Non-interventional
- Observational study
- Single arm study
- Open (masking not used)
- [---]*
- Uncontrolled/Single arm
- Treatment
- Single (group)
- N/A
- N/A
Primary Outcome
The primary efficacy evaluation will be the following values at six month relative to baseline:
a) change in the extent of heart failure (NYHA class)
b) Quality of Life as measured by the Minnesota Living with Heart Failure Questionnaire
c) assessing the performance of a patient below the anaerobic threshold by using the Six-Minute Hall Walk
Secondary Outcome
Secondary Objectives
1. The following data at 12 months compared to pre-implant baseline:
a. Extend of heartfailure measured by NYHA Class
b. Quality of Life with the Minnesota Living with Heart failure Questionnaire
c. Performance of the patient assed with the Six-Minute Hall Walk
d. Biomarker for grade of heart falure (NT-pro-BNP)
e. Heartfunction assessed with Left ventricular ejection fraction (LVEF)
2. The rate of all-cause mortality and cardiovascular mortality at 12 months
3. The following data at 12 months compared to to the 12 months period pre-implant:
a. Heart failure hospitalization
b. Number of episodes
c. Total days hospitalized
d. Total cost of hospitalization
e. Incidence of ventricular and atrial tachyarrhythmias
Countries of Recruitment
- Germany
- Italy
Locations of Recruitment
- Medical Center
- Medical Center
- Medical Center
- Medical Center
- Medical Center
- Medical Center
- Medical Center
- Medical Center
- Medical Center
Recruitment
- Actual
- 2017/04/07
- 500
- Multicenter trial
- International
Inclusion Criteria
- Both, male and female
- 18 Years
- no maximum age
Additional Inclusion Criteria
To be eligible for this registry, subjects must meet all of the following inclusion criteria:
1. Implanted with the Barostim Neo system per the CE-Mark approved criteria for heart failure at any time in the past.
2. On stable, maximally-tolerated, guideline-directed heart failure medications for at least 30 days prior to implant, where stable is defined as:
• No more than a 100% increase or a 50% decrease of the dosage of any one medication other than a diuretic.
• Medication changes within a drug class are allowed as long as the equivalent dosage is within the limits specified above.
• Unrestricted changes in diuretics are allowed as long as the subject remains on a diuretic.
3. Signed a CVRx-approved informed consent form for the registry.
Exclusion Criteria
Patient does not meet inclusion criteria
Addresses
-
start of 1:1-Block address primary-sponsor
- CVRx Incorporated
- 9201 West Broadway Avenue, Suite 650
- MN 55445 Minneapolis
- United States
end of 1:1-Block address primary-sponsorstart of 1:1-Block address contact primary-sponsor- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact primary-sponsor -
start of 1:1-Block address scientific-contact
- CVRx Incorporated
- Ms. Liz Galle
- 9201 West Broadway Avenue, Suite 650
- MN 55445 Minneapolis
- United States
end of 1:1-Block address scientific-contactstart of 1:1-Block address contact scientific-contact- 001 763.416.2331
- [---]*
- lgalle at cvrx.com
- [---]*
end of 1:1-Block address contact scientific-contact -
start of 1:1-Block address public-contact
- CVRx Incorporated
- Ms. Liz Galle
- 9201 West Broadway Avenue, Suite 650
- MN 55445 Minneapolis
- United States
end of 1:1-Block address public-contactstart of 1:1-Block address contact public-contact- 001 763.416.2331
- [---]*
- lgalle at cvrx.com
- [---]*
end of 1:1-Block address contact public-contact
Sources of Monetary or Material Support
-
start of 1:1-Block address materialSupport
- CVRx Incorporated
- 9201 West Broadway Avenue, Suite 650
- MN 55445 Minneapolis
- United States
end of 1:1-Block address materialSupportstart of 1:1-Block address contact materialSupport- [---]*
- [---]*
- [---]*
- [---]*
end of 1:1-Block address contact materialSupport
Status
- Recruiting ongoing
- [---]*
Trial Publications, Results and other Documents
- [---]*